Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Cited by (1,012)

Items 801–900 of 1,012

1. Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons
   Antoine Hollebecque, David Malka, Charles Ferté, Michel Pierre Ducreux, Valérie Boige · 2015 · European Journal of Cancer
2. Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference
   Daniel S.W. Tan, Marco Gerlinger, Bin Tean Teh, Charles Swanton · 2010 · European Journal of Cancer
3. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer
   Xiaolin Zhu, Ling Shan, F. Wang, J. Wang, F. Wang, Guihua Shen, Xiaonan Liu, Binbin Wang, Y. Yuan, Jianming Ying et al. · 2015 · Breast Cancer Research and Treatment
4. Defective homologous recombination in human cancers
   Aiste Cerbinskaite, Asima Mukhopadhyay, Elizabeth Ruth Plummer, Nicola J. Curtin, Richard John Edmondson · 2011 · Cancer Treatment Reviews
5. Breast Cancer Chemoprevention: Old and New Approaches
   Massimiliano Cazzaniga, Bernardo Bonanni · 2012 · BioMed Research International
6. A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors
   Bastiaan Evers, Eva Schut, Eline van der Burg, Tanya M. Braumuller, David A. Egan, Henne H. Holstege, Pauline A. H. Edser, David J. Adams, Richard Wade‐Martins, Peter Bouwman et al. · 2009 · Clinical Cancer Research
7. Regulatory roles of tankyrase 1 at telomeres and in DNA repair: suppression of T-SCE and stabilization of DNA-PKcs
   Ryan C. Dregalla, Junqing Zhou, Rupa Idate, Christine L. R. Battaglia, Howard L. Liber, Susan M. Bailey · 2010 · Aging
8. Critical parameters in targeted drug development: the pharmacological audit trail
   Udai Banerji, Paul Workman · 2016 · Seminars in Oncology
9. PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies
   Loren Scott Michel, Samantha L. Dyroff, Frank J. Brooks, Katherine J. Spayd, Sora Lim, Jacquelyn T. Engle, Sharon E. Phillips, Benjamin R. Tan, Andrea Wang‐Gillam, Christopher Bognar et al. · 2016 · Radiology
10. Polycomb group proteins in the DNA damage response: A link between radiation resistance and “stemness”
    Gieni, Randall S., Ismail, Ismail H., Campbell, Stuart, Hendzel, Michael J. · 2011 · Cell Cycle
11. Missed therapeutic and prevention opportunities in women with BRCA‐mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature
    Paul J Hoskins, Walter Henri Gotlieb · 2017 · CA A Cancer Journal for Clinicians
12. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
    Emily A. Nizialek, Emmanuel S. Antonarakis · 2020 · Cancer Management and Research
13. Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications
    Roberto Moretto, Andrew Elliott, Jian Zhang, Hiroyuki Arai, Marco Maria Germani, Veronica Conca, Joanne Xiu, Phillip Stafford, Matthew James Oberley, Jim P. Abraham et al. · 2021 · JNCI Journal of the National Cancer Institute
14. Development of a Next-Generation Sequencing Method for BRCA Mutation Screening
    Maurice Chan, Shen Mo Ji, Zhen Xuan Yeo, Linda Gan, Eric P.H. Yap, Yoon Sim Yap, Raymond Chee Hui Ng, Puay Hoon Tan, Gay Hui Ho, Peter Ang et al. · 2012 · Journal of Molecular Diagnostics
15. Inactivation of Brca2 Promotes Trp53-Associated but Inhibits KrasG12D-Dependent Pancreatic Cancer Development in Mice
    Matthew Rowley, Akihiro Ohashi, Gourish Mondal, Lisa Mills, Lin Yang, Lizhi Zhang, Rhianna S. Sundsbak, Virginia Smith Shapiro, Michael H. Muders, Thomas C. Smyrk et al. · 2011 · Gastroenterology
16. Translational and clinical implications of the genetic landscape of prostate cancer
    Daniel Eidelberg Spratt, Zachary Stephan Zumsteg, Felix Yi-Chung Feng, Scott A. Tomlins · 2016 · Nature Reviews Clinical Oncology
17. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
    Mark M. Yarchoan, Melinda C. Myzak, Burles Avner Johnson, Ana De Jesus‐Acosta, Dung Thi Le, Elizabeth M. Jaffee, Nilofer Saba Azad, Ross C. Donehower, Lei Zheng, Paul E. Oberstein et al. · 2017 · Oncotarget
18. Aberrations in DNA repair pathways in cancer and therapeutic significances
    Akira Motegi, Mitsuko Masutani, Kenichi Yoshioka, Tadayoshi Bessho · 2019 · Seminars in Cancer Biology
19. Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer
    Nicola J. Curtin · 2013 · British Journal of Pharmacology
20. Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer
    Hiroyuki Yamamoto · 2012 · World Journal of Gastroenterology
21. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor
    Hideaki Ogiwara, Ayako Ui, Bunsyo Shiotani, Lee Zou, Akira Yasui, Takashi Kohno · 2013 · Carcinogenesis
22. Molecular heterogeneity of triple-negative breast cancer and its clinical implications
    Sheeba Irshad, PA Ellis, Andrew N.J. Tutt · 2011 · Current Opinion in Oncology
23. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
    Richard H. Wilson, TR Jeffry Evans, Mark Ross Middleton, L. Rhoda Molife, James F. Spicer, Veronique C Dieras, Patricia Roxburgh, Heidi Giordano, Sarah Jaw‐Tsai, Sandra M. Goble et al. · 2017 · British Journal of Cancer
24. A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
    Kim A. Reiss, Joseph M. Herman, MARIANNA L. ZAHURAK, Anthony M. Brade, Laura Ann Dawson, Angela Scardina, Caitlin Joffe, Emily Petito, Amy Hacker‐Prietz, Robert J. Kinders et al. · 2014 · Clinical Cancer Research
25. Personalized Medicine: The Road Ahead
    Rutika Jitesh Mehta, Rohit Jain, Sunil Badve · 2011 · Clinical Breast Cancer
26. Neoadjuvant Chemotherapy Is Associated with Improved Survival Compared with Adjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer Only after Complete Pathologic Response
    Carla Suzanne Fisher, Cynthia X. Ma, William E. Gillanders, Rebecca Aft, Timothy J. Eberlein, Feng Gao, Julie A. Margenthaler · 2011 · Annals of Surgical Oncology
27. FBH1 influences DNA replication fork stability and homologous recombination through ubiquitylation of RAD51
    Wai Kit Chu, Miranda Payne, Petra Beli, Katsuhiro Hanada, Chunaram Choudhary, Ian David Hickson · 2015 · Nature Communications
28. Mouse models of BRCA1 and their application to breast cancer research
    Jennifer L. Dine, Chu‐Xia Deng · 2012 · Cancer and Metastasis Reviews
29. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
    Alison J Wiggans, Gemma K.S. Cass, Andrew Bryant, Theresa Anne Lawrie, Jo Morrison · 2015 · Cochrane Database of Systematic Reviews
30. Epithelial ovarian cancer risk: A review of the current genetic landscape
    Nicola Flaum, Emma Jayne Crosbie, Richard John Edmondson, Miriam Jane Smith, D. Gareth Evans · 2019 · Clinical Genetics
31. Breast cancer intratumor genetic heterogeneity: causes and implications
    Charlotte K.Y. Ng, Helen N. Pemberton, Jorge Sergio Reis-Filho · 2012 · Expert Review of Anticancer Therapy
32. PARP1 is required for chromosomal translocations
    Justin W. Wray, Elizabeth A. Williamson, Sudha Singh, Yuehan Wu, Christopher Ramin Cogle, David M. Weinstock, Yu Zhang, Suk‐Hee Lee, Daohong Zhou, Lijian Shao et al. · 2013 · Blood
33. Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma
    Stephen A. Watt, Céline Pourreyron, Karin J. Purdie, Catherine Hogan, Clare L. Cole, Nicola A. Foster, Norman Pratt, Jean‐Christophe Bourdon, V. Appleyard, K Murray et al. · 2011 · Oncogene
34. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
    Anneleen Daemen, Denise M. Wolf, James E. Korkola, Obi L. Griffith, Jessica R. Frankum, Rachel Brough, Lakshmi R. Jakkula, Nicholas J. Wang, Rachael Natrajan, Jorge Sergio Reis-Filho et al. · 2012 · Breast Cancer Research and Treatment
35. Human Nuclease/Helicase DNA2 Alleviates Replication Stress by Promoting DNA End Resection
    Guang Peng, Hui Dai, Wei Zhang, Hui-Ju Hsieh, Mei‐Ren Pan, Yun‐Yong Park, Robert Y. L. Tsai, Isabelle Bedrosian, Ju‐Seog Lee, Grzegorz Ira et al. · 2012 · Cancer Research
36. Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology
    Kinnersley, Ben, Sud, Amit, Everall, Andrew, Cornish, Alex J., Chubb, Daniel, Culliford, Richard, Gruber, Andreas J., Lärkeryd, Adrian, Mitsopoulos, Costas, Wedge, David et al. · 2024 · Nature Genetics
37. Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine
    Masayuki Nagahashi, Toshifumi Wakai, Yoshifumi Shimada, Hiroshi Ichikawa, Hitoshi Kameyama, Takashi Kobayashi, Jun Sakata, Ryoma Yagi, Nobuaki Sato, Yuko Kitagawa et al. · 2016 · Genome Medicine
38. RETRACTED ARTICLE: Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer
    Wael Yassin Mansour, Pierre Tennstedt, Jennifer Volquardsen, Christoph Oing, Martina Kluth, Claudia Hube‐Magg, Kerstin Borgmann, Ronald Simon, Cordula Petersen, Ekkehard Dikomey et al. · 2018 · Scientific Reports · Retracted
39. Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon
    Babatunde Adedokun, Yonglan Zheng, Paul Ndom, Antony Gakwaya, Timothy Makumbi, Alicia Yiran Zhou, Toshio F. Yoshimatsu, Alex Rodriguez, Ravi Madduri, Ian T Foster et al. · 2019 · Cancer Epidemiology Biomarkers & Prevention
40. PARP inhibitors in ovarian cancer: An overview of the practice‐changing trials
    Tiffany Foo, Angela Joy George, Susana N. Banerjee · 2020 · Genes Chromosomes and Cancer
41. Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
    Violeta Serra, Anderson T. Wang, Marta Castroviejo‐Bermejo, Urszula M. Polanska, Marta Palafox, Andrea Herencia-Ropero, Gemma N. Jones, Zhongwu Lai, Joshua Armenia, Filippos Michopoulos et al. · 2022 · Clinical Cancer Research
42. The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies
    Haochuan Guo, Xinru Xu, Jiaxi Zhang, Yajing Du, Xinbing Yang, Zhiheng He, Linjie Zhao, Tingming Liang, Li Guo · 2024 · Pharmaceuticals
43. A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors*,†
    Noboru Yamamoto, Hiroshi Nokihara, Yasuhide Yamada, Yasushi Goto, Maki Tanioka, Takashi Shibata, Kazuhiko Yamada, Hajime Asahina, Toshio Kawata, Xiaojin Shi et al. · 2011 · Cancer Science
44. African American Women's Limited Knowledge and Experiences with Genetic Counseling for Hereditary Breast Cancer
    Vanessa B. Sheppard, Kristi D. Graves, Juleen Christopher, Alejandra Hurtado‐de‐Mendoza, Costellia H. Talley, Karen Patricia Williams · 2013 · Journal of Genetic Counseling
45. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
    Tesa Severson, Denise M. Wolf, Christina S. F. Yau, Justine K. Peeters, Diederik Wehkam, Philip C. Schouten, Suet‐Feung Chin, Ian J. Majewski, Magali Michaut, Astrid R. Bosma et al. · 2017 · Breast Cancer Research
46. PARP10 promotes cellular proliferation and tumorigenesis by alleviating replication stress
    Emily M. Schleicher, Adri M. Galvan, Yuka Imamura Kawasawa, George‐Lucian Moldovan, Claudia M. Nicolae · 2018 · Nucleic Acids Research
47. BRCA mutated pancreatic cancer: A change is coming
    Michael N. Rosen, Rachel Anne Goodwin, Michael M. Vickers · 2021 · World Journal of Gastroenterology
48. Optimization of Phenyl-Substituted Benzimidazole Carboxamide Poly(ADP-Ribose) Polymerase Inhibitors: Identification of (S)-2-(2-Fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a Highly Potent and Efficacious Inhibitor
    Thomas D. Penning, Gui‐Dong Zhu, Jianchun Gong, Sheela A. Thomas, Viraj B. Gandhi, Xuesong Liu, Yan Shi, Vered Klinghofer, Eric Feral Johnson, Chang H. Park et al. · 2010 · Journal of Medicinal Chemistry
49. Key concepts in glioblastoma therapy
    Jiri Jr Bartek, Kimberly Ng, Jiri Jr Bartek, Walter Fischer, Bob S. Carter, Clark C. Chen · 2012 · Journal of Neurology Neurosurgery & Psychiatry
50. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer
    Anthony Eccleston, Anthony Bentley, Matthew Dyer, Ann Strydom, Wim Vereecken, Angela Joy George, Nazneen Rahman · 2017 · Value in Health
51. Potential of the Synthetic Lethality Principle
    Sebastian M. B. Nijman, Stephen Henry Friend · 2013 · Science
52. Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma
    Wael Yassin Mansour, Natalia Viktorovna Bogdanova, Ulla Kasten-Pisula, Thorsten Rieckmann, Sabrina Köcher, Kerstin Borgmann, Michael A. Baumann, Mechthild Krause, Cordula Petersen, Hailiang Hu et al. · 2012 · Radiotherapy and Oncology
53. Inherited Mutations in Breast Cancer Genes—Risk and Response
    Andrew Y. Shuen, William D. Foulkes · 2011 · Journal of Mammary Gland Biology and Neoplasia
54. Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective
    Marcel Verheij, Conchita Vens, Baukelien van Triest · 2010 · Drug Resistance Updates
55. HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair
    Somaira Nowsheen, Tiffiny S. Cooper, James A. Bonner, Albert F. LoBuglio, Eddy Shih-Hsin Yang · 2012 · Cancer Research
56. Multistage Vectored siRNA Targeting Ataxia‐Telangiectasia Mutated for Breast Cancer Therapy
    Rong Xu, Yi Huang, Junhua Mai, Guodong Zhang, Xiaojing Guo, Xiaojun Xia, Eugene Jon Koay, Guoting Qin, Donald R. Erm, Qingpo Li et al. · 2013 · Small
57. Generation of small molecules to interfere with regulated necrosis
    Alexei Degterev, Andreas Linkermann · 2016 · Cellular and Molecular Life Sciences
58. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
    Jai Narendra Patel, Elena Ioana Braicu, Kirsten M. Timms, Cara Solimeno, Placede Tshiaba, Julia Reid, Jerry S. S. Lanchbury, Silvia Darb‐Esfahani, Mahrukh K. Ganapathi, Jalid Sehouli et al. · 2018 · British Journal of Cancer
59. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma
    David R. Fogelman, Elizabeth A. Sugar, George R. Oliver, Neeraj Nailesh Shah, Alison P. Klein, Christine Alewine, Huamin Wang, Milind M. Javle, Rachna T. Shroff, Robert A. Wolff et al. · 2015 · Cancer Chemotherapy and Pharmacology
60. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment
    Diana P. Saraiva, Maria Guadalupe Cabral, António Jacinto, Sofia Azambuja Braga · 2017 · ESMO Open
61. Recent advancements in synthetic methodologies of 3-substituted phthalides and their application in the total synthesis of biologically active natural products
    Amardeep Awasthi, Mandeep Singh, Garima Rathee, Ramesh Chandra · 2020 · RSC Advances
62. Biology-driven therapy advances in high-grade serous ovarian cancer
    Yinu Wang, Alexander James Duval, Mazhar Adli, Daniela Elena Matei · 2024 · Journal of Clinical Investigation
63. Radiosensitization effect of poly( ADP ‐ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation
    Takahisa Hirai, Hidenori Shirai, Hiroaki Fujimori, Ryuichi Okayasu, Keisuke Sasai, Mitsuko Masutani · 2012 · Cancer Science
64. Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?
    Mónica Arnedos, Jean‐Charles Soria, Fabrice André, Thomas Tursz · 2014 · Cancer Treatment Reviews
65. Using synthetic DNA interstrand crosslinks to elucidate repair pathways and identify new therapeutic targets for cancer chemotherapy
    Angelo Guainazzi, Orlando D. Schärer · 2010 · Cellular and Molecular Life Sciences
66. Predicting Recurrence After Radiotherapy in Head and Neck Cancer
    Adrian C. Begg · 2012 · Seminars in Radiation Oncology
67. Differing Clinical Impact of BRCA1 and BRCA2 Mutations in Serous Ovarian Cancer
    Guoyan Liu, Da Yang, Yan Kui Sun, Ilya Shmulevich, Fengxia Xue, Anil K. Sood, Wei Zhang · 2012 · Pharmacogenomics
68. TGFβ Induces “BRCAness” and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes
    Liang Liu, Weiying Zhou, Chun-Ting Cheng, Xiubao Ren, George Somlo, Miranda Fong, Andrew R. Chin, Hui Li, Yang Yu, Yang Xu et al. · 2014 · Molecular Cancer Research
69. Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer
    Somaira Nowsheen, James A. Bonner, Albert F. LoBuglio, Hoa Quang Trummell, Alexander C. Whitley, Michael Christian Dobelbower, Eddy Shih-Hsin Yang · 2011 · PLoS ONE
70. Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
    Ursula Kortmann, Jessica Nell McAlpine, Hui Xue, Jun Guan, Gavin Ha, Sophie Tully, Sharaz Shafait, Alan Lau, Aaron N. Cranston, Mark J. O’Connor et al. · 2010 · Clinical Cancer Research
71. The Korean Hereditary Breast Cancer (KOHBRA) Study: Protocols and Interim Report
    Sang‐Ah Han, Sung Sup Park, Sei Hyun Ahn, Min Hyuk Lee, Dong‐Young Noh, Lee Su Kim, Woo-Chul Noh, Yong Sik Jung, Ku Sang Kim, Sung‐Won Kim et al. · 2011 · Clinical Oncology
72. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
    Ymera Pignochino, Federica Capozzi, Lorenzo D’Ambrosio, Carmine Dell’Aglio, Marco Basiricò, Marta Canta, Annalisa Lorenzato, Francesca Vignolo Lutati, Sandra Aliberti, Erica Palesandro et al. · 2017 · Molecular Cancer
73. PARPs in genome stability and signal transduction: implications for cancer therapy
    Luca Palazzo, Ivan Ahel · 2018 · Biochemical Society Transactions
74. Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells
    Kristen E. Clements, Tanay Thakar, Claudia M. Nicolae, Xinwen Liang, Hong‐Gang Wang, George‐Lucian Moldovan · 2018 · Nucleic Acids Research
75. The development of PARP inhibitors in ovarian cancer: from bench to bedside
    Yvette Drew · 2015 · British Journal of Cancer
76. PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
    Hao‐Wen Sim, Evanthia Galanis, Mustafa Khasraw · 2022 · Cancers
77. Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1
    Jingjie Yi, Huan Li, Bo Chu, Ning Kon, Xiaoping Hu, Jianping Hu, Yan Xiong, H. Ümit Kanıskan, Jian Jun Jin, Wei Jun Gu · 2023 · Cell Death and Differentiation
78. Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis
    Anthony Gonçalvès, Pascal Finetti, Renaud Sabatier, Marine Gilabert, José Adélaı̈de, Jean‐Paul Borg, Max Chaffanet, Patrice Viens, Daniel Birnbaum, François Bertucci · 2010 · Breast Cancer Research and Treatment
79. Inhibiting homologous recombination for cancer therapy
    Sophia B. Chernikova, John C. Game, J. Martin Brown · 2012 · Cancer Biology & Therapy
80. DNA repair in cancer: emerging targets for personalized therapy
    Srinivasan Madhusudan, Rachel Abbotts, Nicola Thompson · 2014 · Cancer Management and Research
81. Targeting poly(ADP-ribose) polymerase activity for cancer therapy
    Frédérique Mégnin-Chanet, Marc A. Bollet, Janet A. Hall · 2010 · Cellular and Molecular Life Sciences
82. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
    Shahneen Kaur Sandhu, Aurelius Gabriel Omlin, Lucy Hylands, Susana Miranda, Louise J. Barber, Ruth Riisnaes, Alison H.M. Reid, Gerhardt Attard, L. Chen, Iwanka Kozarewa et al. · 2013 · Annals of Oncology
83. Successes and Challenges of PARP Inhibitors in Cancer Therapy
    Tiffany K. Ricks, Haw-Jyh Chiu, Gwynn Ison, Geoffrey Kim, Amy E. McKee, Paul Gustav Kluetz, Richard Pazdur · 2015 · Frontiers in Oncology
84. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer
    Priyanka Sharma · 2018 · Current Treatment Options in Oncology
85. The human VRK1 chromatin kinase in cancer biology
    Ignacio Campillo‐Marcos, Raúl García-González, Elena Navarro-Carrasco, Pedro A. Lazo · 2021 · Cancer Letters
86. Chemoprevention of Hormone Receptor-Negative Breast Cancer: New Approaches Needed
    Iván P. Uray, Powel H. Brown · 2010 · Recent results in cancer research/Recent Results in Cancer Research
87. Molecular Profiling of Cancer—The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic
    Thomas P. Stricker, Daniel V.T. Catenacci, Tanguy Y. Seiwert · 2011 · Seminars in Oncology
88. Time for more optimism in metastatic breast cancer?
    Elżbieta Senkus, Fátima Cardoso, Olivia Pagani · 2013 · Cancer Treatment Reviews
89. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions
    D H Moon, J-M Lee, Anne M. Noonan, Christina M. Annunziata, Lori M. Minasian, Nicole D. Houston, John L. Hays, Elise C. Kohn · 2013 · British Journal of Cancer
90. Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents
    Christophe Le Tourneau, Veronique C Dieras, Patricia Tresca, Wulfran Cacheux, Xavier Paolettí · 2010 · Targeted Oncology
91. Repair mechanisms help glioblastoma resist treatment
    Ryan J. Atkins, Wayne Ng, Stanley S. Stylli, Christopher M. Hovens, Andrew H. Kaye · 2014 · Journal of Clinical Neuroscience
92. Personalized medicine: hope or hype?
    Keyan Salari, Hugh C Watkins, Euan Angus Ashley · 2012 · European Heart Journal
93. Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
    Yunfeng Cui, Jacqueline A. Brosnan‐Cashman, Amanda L. Blackford, Surojit Sur, Ralph H. Hruban, Kenneth W. Kinzler, Bert Vogelstein, Anirban Maitra, Luis Alberto Diaz, Christine A. Iacobuzio–Donahue et al. · 2012 · Clinical Cancer Research
94. Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities
    Nicola Normanno, Anna Maria Rachiglio, Cristin Roma, Francesca Fenizia, Claudia Esposito, Raffaella Pasquale, Maria Libera La Porta, Alessia Iannaccone, Filippo Micheli, Michele L Santangelo et al. · 2012 · Journal of Cellular Biochemistry
95. Synthetic Lethal Screens as a Means to Understand and Treat MYC-Driven Cancers
    Silvia Cermelli, In Sock Jang, Brady M. Bernard, Carla Grandori · 2014 · Cold Spring Harbor Perspectives in Medicine
96. Identification of a claudin‐4 and E‐cadherin score to predict prognosis in breast cancer
    Attila Marcell Szász, Zsuzsanna Németh, Balázs Győrffy, Mariann Micsinai, Tibor Krenács, Zsolt Baranyai, László Harsányi, András Kiss, Zsuzsa Schaff, Anna‐Mária Tõkés et al. · 2011 · Cancer Science
97. Prostate cancer genes associated with TMPRSS2–ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts
    Benjamin G. Barwick, Mark Abramovitz, Maja Kodani, Carlos S. Moreno, R. K. Nam, Weining Tang, Mark Bouzyk, Arun K. Seth, Bryan Leyland-Jones · 2010 · British Journal of Cancer
98. Present and future evolution of advanced breast cancer therapy
    Ricardo H. Álvarez · 2010 · Breast Cancer Research
99. Monogenic Diseases of DNA Repair
    Guido Keijzers, Daniela Bakula, Morten Scheibye‐Knudsen · 2017 · New England Journal of Medicine
100. A Cell-Line-Specific Atlas of PARP-Mediated Protein Asp/Glu-ADP-Ribosylation in Breast Cancer
     Yuanli Zhen, Yajie Zhang, Yonghao Yu · 2017 · Cell Reports